Convertibles Calendar: Cerevel Therapeutics on tap

Aug. 11

CEREVEL THERAPEUTICS HOLDINGS INC.:

• $250 million five-year convertible notes

• $37.5 million greenshoe

• Coupon of 2.75% to 3.25% and initial conversion premium of 27.5% to 32.5%

• Non-callable until Aug. 20, 2025 and then subject to a 130% hurdle

• Rule 144A

• Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Jefferies LLC and Evercore

• Concurrent secondary offering of $250 million common stock

• Research and development for products in its pipeline and for general corporate purposes

• Cambridge, Mass-based biopharmaceutical company focused on neurological diseases

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.